Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 20:14 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma
NCT04150562 · National Cancer Institute (NCI) · PHASE2 · terminated · last registry update 2022-05-17 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “This study was terminated early due to manufacturer withdrawal of support (study medication) due to lack of enrollment.” | – | Registry record, National Cancer Institute (NCI) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL2RG within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-05-15Results posted on the registry: Barbara Ann Karmanos Cancer Institute, Aldesleukin + Antibody Therapy (NCT02620865)
- 2023-03-21Results posted on the registry: City of Hope Medical Center, aldesleukin + filgrastim (NCT00534469)
- 2023-03-06Results posted on the registry: National Cancer Institute (NCI), rh IL-15 (10 DAYS) + rh IL-15 (5 DAYS) (NCT01572493)
- 2023-03-03Results posted on the registry: Masonic Cancer Center, University of Minnesota, Aldesleukin: All Patients + Nivolumab: Cohort 1 (Cutaneous) (NCT03850691)
- 2023-02-24Results posted on the registry: St. Jude Children's Research Hospital, cyclophosphamide + topotecan (NCT01857934)
- 2023-02-21Results posted on the registry: Hoffmann-La Roche, simlukafusp alfa + Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody (NCT03386721)
- 2023-02-21Also stopped (terminated): Hoffmann-La Roche, simlukafusp alfa + Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody (NCT03386721)
- 2023-02-14Also stopped (withdrawn): Carman Giacomantonio, Interleukin-2 + Combination therapy Interleukin-2 and Bacillus Calmette Guerin (NCT03928275)
- 2023-02-09Results posted on the registry: Rutgers, The State University of New Jersey, Aldesleukin + Pembrolizumab (NCT02748564)
- 2023-02-01Results posted on the registry: Washington University School of Medicine, Fludarabine + Cyclophosphamide (NCT01898793)
- 2023-01-18Results posted on the registry: National Cancer Institute (NCI), Aldesleukin + Fludarabine (NCT01993719)
- 2022-11-30Phase 3 first posted: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Human umbilical cord mesenchymal stem cells + Interleukin-2 (NCT05631717)
- 2022-11-15Also stopped (terminated): Fred Hutchinson Cancer Center, therapeutic autologous lymphocytes + aldesleukin (NCT00945269)
- 2022-11-10Results posted on the registry: Fred Hutchinson Cancer Center, Aldesleukin + Cyclophosphamide (NCT01807182)
- 2022-11-04Also stopped (terminated): University of Cologne, antibody ch14.18 + GM-CSF (NCT02641782)
- 2022-09-29Results posted on the registry: University of California, Los Angeles, Basiliximab + Tacrolimus (NCT02123108)
- 2022-09-28Results posted on the registry: St. Jude Children's Research Hospital, dexamethasone + vincristine sulfate (NCT01700946)
- 2022-09-28Results posted on the registry: Case Western Reserve University, Recombinant Interleukin-2 (NCT03308786)
- 2022-09-28Also stopped (terminated): Case Western Reserve University, Recombinant Interleukin-2 (NCT03308786)
- 2022-09-13Results posted on the registry: National Cancer Institute (NCI), rhIL-15 + rhIL-15 (NCT03905135)
- 2022-08-31Also stopped (terminated): Centre Hospitalier Universitaire de Nice, Interleukin-2 (NCT01840046)
- 2022-08-18Also stopped (suspended): PACT Pharma, Inc., NeoTCR-P1 adoptive cell therapy + nivolumab (NCT03970382)
- 2022-08-10Phase 3 first posted: Peking University People's Hospital, Interleukin-2 (NCT05495321)
- 2022-07-25Also stopped (terminated): Yale University, Tumor Infiltrating Lymphocytes + Nivolumab and Ipilimumab (NCT03526185)
- 2022-07-14Also stopped (terminated): Fred Hutchinson Cancer Center, Aldesleukin + Cyclophosphamide (NCT01640301)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision